Ionis to hold second quarter 2024 financial results webcast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
July 22, 2024 1:06 PM EDTJefferies analyst Akash Tewari raised the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $77.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "IONS released Angelman data this AM - overall we thought the data (albeit early) looks ok/encouraging: 1) IONS582's efficacy... More
Goldman Sachs Reiterates Sell Rating on Ionis Pharmaceuticals (IONS)
July 22, 2024 12:04 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Sell rating and $33.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).
The analyst comments "Ahead of the 2024 Angelman Syndrome Foundation conference, IONS reported six-month Ph1/2 data on antisense oligonucleotide (ASO) ION582 in Angelman syndrome (n=11, 13 and 27 at the low, medium and high doses), where 67% of medium/high-dose patients improved vs. natural history,... More
